Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies

Clinical and Experimental Neuroimmunology

Volumn 5, Issue 2, 2014, Pages 175-187

  Iorio, Raffaele ^a   Pittock, Sean J ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b MAYO CLINIC   (United States)

Author keywords

aquaporin; multiple sclerosis; Neuromyelitis optica; optic neuritis; transverse myelitis; water channel

Indexed keywords

ANTIGEN; AQUAPORIN 4; BETA INTERFERON; CORTICOSTEROID; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYELIN;

ANTIDIURESIS; ANTIGEN SPECIFICITY; ASTROCYTE; AUTOIMMUNE AQUAPORIN 4 CHANNELOPATHY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CENTRAL NERVOUS SYSTEM DISEASE; CHANNELOPATHY; CHILDHOOD DISEASE; CORTICOSTEROID THERAPY; DEMYELINATING DISEASE; ENDOCRINE DISEASE; IMAGE ANALYSIS; IMMUNOBIOLOGY; MYELITIS; MYELOOPTIC NEUROPATHY; NAUSEA AND VOMITING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; OPTIC NERVE; OPTIC NEURITIS; PARANEOPLASTIC SYNDROME; PLASMAPHERESIS; PRIORITY JOURNAL; RELAPSE; REVIEW; SLEEP DISORDER; SPINAL CORD;

EID: 84903629094     PISSN: None     EISSN: 17591961     Source Type: Journal    
DOI: 10.1111/cen3.12103     Document Type: Review

References (86)

1. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004; 364 (9451): 2106-12.
2. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR,. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005; 202 (4): 473-7.
3. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG,. The spectrum of neuromyelitis optica. Lancet Neurol. 2007; 6 (9): 805-15.
4. Iorio R, Lennon VA,. Neural antigen-specific autoimmune disorders. Immunol Rev. 2012; 248 (1): 104-21.
5. Mesbah-Benmessaoud OBR, Hardin-Pouzet H, Dorbani-Mamine L, Grange-Messent V,. Cellular and subcellular aquaporin-4 distribution in the mouse neurohypophysis and the effects of osmotic stimulation. J Histochem Cytochem. 2011; 59 (1): 88-97.
6. Jiao Y, Fryer JP, Lennon VA, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology. 2013; 81 (14): 1197-204.
7. Quek AM, McKeon A, Lennon VA, et al. Effects of age and sex on aquaporin-4 autoimmunity. Arch Neurol. 2012; 69 (8): 1039-43.
8. Asgari N, Lillevang ST, Skejoe HP, Falah M, Stenager E, Kyvik KO,. A population-based study of neuromyelitis optica in Caucasians. Neurology. 2011; 76 (18): 1589-95.
9. Jung JS, Bhat RV, Preston GM, Guggino WB, Baraban JM, Agre P,. Molecular characterization of an aquaporin cDNA from brain: candidate osmoreceptor and regulator of water balance. Proc Natl Acad Sci U S A. 1994; 91 (26): 13052-6.
10. Hasegawa H, Ma T, Skach W, Matthay MA, Verkman AS,. Molecular cloning of a mercurial-insensitive water channel expressed in selected water-transporting tissues. J Biol Chem. 1994; 269 (8): 5497-500.
11. Rash JE, Davidson KG, Yasumura T, Furman CS,. Freeze-fracture and immunogold analysis of aquaporin-4 (AQP4) square arrays, with models of AQP4 lattice assembly. Neuroscience. 2004; 129 (4): 915-34.
12. Crane JM, Bennett JL, Verkman AS,. Live cell analysis of aquaporin-4 m1/m23 interactions and regulated orthogonal array assembly in glial cells. J Biol Chem. 2009; 284 (51): 35850-60.
13. Hinson SR, Pittock SJ, Lucchinetti CF, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology. 2007; 69 (24): 2221-31.
14. Hinson SR, Roemer SF, Lucchinetti CF, et al. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med. 2008; 205 (11): 2473-81.
15. Hinson SR, Romero MF, Popescu BF, et al. Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A. 2012; 109 (4): 1245-50.
16. Vincent T, Saikali P, Cayrol R, et al. Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J Immunol. 2008; 181 (8): 5730-7.
17. Iorio R, Fryer JP, Hinson SR, et al. Astrocytic autoantibody of neuromyelitis optica (NMO-IgG) binds to aquaporin-4 extracellular loops, monomers, tetramers and high order arrays. J Autoimmun. 2013; 40: 21-7.
18. Nurieva RI, Chung Y,. Understanding the development and function of T follicular helper cells. Cell Mol Immunol. 2010; 7 (3): 190-7.
19. Saadoun S, Waters P, MacDonald C, et al. Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain. Ann Neurol. 2012; 71 (3): 323-33.
20. Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA. 2011; 108 (9): 3701-6.
21. Zhang H, Verkman AS,. Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica. J Clin Invest. 2013; 123 (5): 2306-16.
22. Fujihara K, Misu T, Nakashima I, et al. Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease. Clin Exp Neuroimmunol. 2012; 3: 58-73.
23. Marignier R, Nicolle A, Watrin C, et al. Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury. Brain. 2010; 133 (9): 2578-91.
24. Barger SW, Goodwin ME, Porter MM, Beggs ML,. Glutamate release from activated microglia requires the oxidative burst and lipid peroxidation. J Neurochem. 2007; 101 (5): 1205-13.
25. Piani D, Fontana A,. Involvement of the cystine transport system xc- in the macrophage-induced glutamate-dependent cytotoxicity to neurons. J Immunol. 1994; 152 (7): 3578-85.
26. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain. 2002; 125 (Pt 7): 1450-61.
27. Roemer SF, Parisi JE, Lennon VA, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain. 2007; 130 (Pt 5): 1194-205.
28. Popescu BF, Lennon VA, Parisi JE, et al. Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology. 2011; 76 (14): 1229-37.
29. Misu T, Hoftberger R, Fujihara K, et al. Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica. Acta Neuropathol. 2013; 125 (6): 815-27.
30. Bennett JL, Lam C, Kalluri SR, et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol. 2009; 66 (5): 617-29.
31. Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC,. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain. 2010; 133 (Pt 2): 349-61.
32. Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol. 2009; 66 (5): 630-43.
33. Kinoshita M, Nakatsuji Y, Kimura T, et al. Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells. Biochem Biophys Res Commun. 2010; 394 (1): 205-10.
34. Jarius S, Frederikson J, Waters P, et al. Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci. 2010; 298 (1-2): 158-62.
35. Weinshenker BG, Wingerchuk DM, Vukusic S, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol. 2006; 59 (3): 566-9.
36. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG,. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006; 66 (10): 1485-9.
37. Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA, Weinshenker BG,. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology. 2007; 68 (8): 603-5.
38. Banwell B, Tenembaum S, Lennon VA, et al. Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology. 2008; 70 (5): 344-52.
39. Ketelslegers IA, Modderman PW, Vennegoor A, Killestein J, Hamann D, Hintzen RQ,. Antibodies against aquaporin-4 in neuromyelitis optica: distinction between recurrent and monophasic patients. Mult Scler. 2011; 17 (12): 1527-30.
40. Nagaishi A, Takagi M, Umemura A, et al. Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes. J Neurol Neurosurg Psychiatry. 2011; 82 (12): 1360-4.
41. Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation. 2012; 9: 14.
42. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG,. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999; 53 (5): 1107-14.
43. Khanna S, Sharma A, Huecker J, Gordon M, Naismith RT, Van Stavern GP,. Magnetic resonance imaging of optic neuritis in patients with neuromyelitis optica versus multiple sclerosis. J Neuroophthalmol. 2012; 32 (3): 216-20.
44. de Seze J, Blanc F, Jeanjean L, et al. Optical coherence tomography in neuromyelitis optica. Arch Neurol. 2008; 65 (7): 920-3.
45. Ratchford JN, Quigg ME, Conger A, et al. Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology. 2009; 73 (4): 302-8.
46. Iorio R, Damato V, Mirabella M, et al. Distinctive clinical and neuroimaging characteristics of longitudinally extensive transverse myelitis associated with aquaporin-4 autoantibodies. J Neurol. 2013; 260 (9): 2396-402.
47. Chang KH, Lyu RK, Chen CM, et al. Distinct features between longitudinally extensive transverse myelitis presenting with and without anti-aquaporin 4 antibodies. Mult Scler. 2013; 19 (3): 299-307.
48. Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA,. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol. 2006; 63 (7): 964-8.
49. Apiwattanakul M, Popescu BF, Matiello M, et al. Intractable vomiting as the initial presentation of neuromyelitis optica. Ann Neurol. 2010; 68 (5): 757-61.
50. Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y,. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology. 2005; 65 (9): 1479-82.
51. Iorio R, Lucchinetti CF, Lennon VA, et al. Intractable nausea and vomiting from autoantibodies against a brain water channel. Clin Gastroenterol Hepatol. 2013; 11 (3): 240-5.
52. Iorio R, Lucchinetti CF, Lennon VA, et al. Syndrome of inappropriate antidiuresis may herald or accompany neuromyelitis optica. Neurology. 2011; 77 (17): 1644-6.
53. McKeon A, Lennon VA, Lotze T, et al. CNS aquaporin-4 autoimmunity in children. Neurology. 2008; 71 (2): 93-100.
54. Tenembaum S, Chitnis T, Ness J, Hahn JS,. Acute disseminated encephalomyelitis. Neurology. 2007; 16 (Suppl 2): S23-36.
55. Ito S, Mori M, Makino T, Hayakawa S, Kuwabara S,. "Cloud-like enhancement" is a magnetic resonance imaging abnormality specific to neuromyelitis optica. Ann Neurol. 2009; 66 (3): 425-8.
56. Magana SM, Matiello M, Pittock SJ, et al. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology. 2009; 72 (8): 712-7.
57. Matthews L, Marasco R, Jenkinson M, et al. Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology. 2013; 80 (14): 1330-7.
58. de Seze J, Blanc F, Kremer S, et al. Magnetic resonance spectroscopy evaluation in patients with neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2010; 81 (4): 409-11.
59. Ciccarelli O, Thomas D, De Vita E, et al. Low myo-inositol indicating astrocytic damage in a case series of NMO. Ann Neurol. 2013; 74: 301-305.
60. Jarius S, Paul F, Franciotta D, et al. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci. 2011; 306 (1-2): 82-90.
61. Misu T, Takano R, Fujihara K, Takahashi T, Sato S, Itoyama Y,. Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker. J Neurol Neurosurg Psychiatry. 2009; 80 (5): 575-7.
62. Takano R, Misu T, Takahashi T, Sato S, Fujihara K, Itoyama Y,. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology. 2010; 75 (3): 208-16.
63. Uzawa A, Mori M, Arai K, et al. Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler. 2010; 16 (12): 1443-52. [Epub ahead of print].
64. Pittock SJ, Lennon VA, de Seze J, et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol. 2008; 65 (1): 78-83.
65. Wingerchuk DM, Weinshenker BG,. The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler. 2012; 18 (1): 5-10.
66. McKeon A, Lennon VA, Jacob A, et al. Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle Nerve. 2009; 39 (1): 87-90.
67. Pittock SJ, Lennon VA,. Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol. 2008; 65 (5): 629-32.
68. De Santis G, Caniatti L, De Vito A, De Gennaro R, Granieri E, Tola MR,. A possible paraneoplastic neuromyelitis optica associated with lung cancer. Neurol Sci. 2009; 30 (5): 397-400.
69. Armagan H, Tuzun E, Icoz S, et al. Long extensive transverse myelitis associated with aquaporin-4 antibody and breast cancer: favorable response to cancer treatment. J Spinal Cord Med. 2012; 35 (4): 267-9.
70. Frasquet M, Bataller L, Torres-Vega E, et al. Longitudinally extensive transverse myelitis with AQP4 antibodies revealing ovarian teratoma. J Neuroimmunol. 2013; 263 (1-2): 145-7.
71. Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology. 2012; 78 (9): 665-71. discussion 9.
72. Marignier R, Bernard-Valnet R, Giraudon P, et al. Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity. Neurology. 2013; 80 (24): 2194-200.
73. Jarius S, Aboul-Enein F, Waters P, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain. 2008; 131 (Pt 11): 3072-80.
74. Magana SM, Keegan BM, Weinshenker BG, et al. Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol. 2011; 68 (7): 870-8.
75. Papeix C, Vidal JS, de Seze J, et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler. 2007; 13 (2): 256-9.
76. Palace J, Leite MI, Nairne A, Vincent A,. Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol. 2010; 67 (8): 1016-7.
77. Kleiter I, Hellwig K, Berthele A, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol. 2012; 69 (2): 239-45.
78. Min JH, Kim BJ, Lee KH,. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler. 2012; 18 (1): 113-5.
79. Costanzi C, Matiello M, Lucchinetti CF, et al. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology. 2011; 77 (7): 659-66.
80. Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C,. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005; 7: 1270-2.
81. Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ,. A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder. JAMA Neurol. 2013; 70 (9): 1110-7.
82. Pittock SJ, Lennon VA, McKeon A, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 2013; 12 (6): 554-62.
83. Kieseier BC, Stuve O, Dehmel T, et al. Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol. 2013; 70 (3): 390-3.
84. Ayzenberg I, Kleiter I, Schroder A, et al. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol. 2013; 70 (3): 394-7.
85. Petzold A, Pittock S, Lennon V, Maggiore C, Weinshenker BG, Plant GT,. Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. J Neurol Neurosurg Psychiatry. 2010; 81 (1): 109-11.
86. Jiao Y, Fryer JP, Lennon VA, et al. Aquaporin 4 IgG serostatus and outcome in recurrent longitudinally extensive transverse myelitis. JAMA Neurol. 2014; 71 (1): 48-54.